MYRIAD GENETICS INC
MYGNNasdaq
$6.18
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +22.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$579.1M
Enterprise Value
$575.0M
P/E
—
P/S
0.7
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$829.0M
Net Income (TTM)
-$400.0M
Free Cash Flow (TTM)
—
Gross Margin
70.0%
Operating Margin
-46.9%
Net Margin
-48.3%
ROE
-118.5%
ROIC
-92.2%
Debt / Equity
0.4
Net Cash
$4.1M
Return 1Y
+28.2%
Company profile
Myriad Genetics, Inc. develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers.
- CEO
- Paul J. Diaz
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2,600
- Headquarters
- Utah
- Website
- myriad.com
Management & directors
- Donnelly Brian JChief Commerical Officer
- Raha Samraat S.President and CEO
- Jampa RajChief Technology Officer
- Muzzey DaleChief Scientific Officer
- Verratti MarkChief Operating Officer
- Wheeler Benjamin RichardChief Financial Officer
- Haas Kevin RichardChief Technology Officer
- Solaiman ShereenChief People Officer
- Fox Jennifer LynneChief Legal Officer
- Ancona MargaretEVP, Strategy & Transformation
- Munk NatalieChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
MYGN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$200.4M↑ +2.3%
Diluted EPS-$0.36—
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $557.1M | $690.6M | $678.4M | $753.2M | $837.6M | $824.5M |
| Gross profit | — | — | $476.4M | $517.0M | $585.4M | $576.6M |
| Operating income | -$289.7M | -$190.5M | -$140.6M | -$257.4M | -$123.5M | -$387.2M |
| Net income | -$223.6M | -$27.0M | -$112.0M | -$263.0M | -$127.0M | -$366.0M |
| Diluted EPS | -$2.99 | -$0.35 | -$1.39 | -$3.18 | -$1.41 | -$3.95 |
| Operating cash flow | — | $18.6M | -$106.3M | -$110.9M | -$8.7M | $1.8M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | 70.2% | 68.6% | 69.9% | 69.9% |
| Operating margin | -52.0% | -27.6% | -20.7% | -34.2% | -14.7% | -47.0% |
| Net margin | -40.1% | -3.9% | -16.5% | -34.9% | -15.2% | -44.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $211.5M | $213.3M | $210.6M | $195.9M | $213.1M | $205.7M | $209.8M | $200.4M |
| Gross profit | $147.1M | $149.8M | $150.9M | $134.2M | $151.8M | $143.8M | $146.8M | $137.6M |
| Operating income | -$36.5M | -$20.0M | -$39.1M | -$29.0M | -$329.2M | -$23.3M | -$5.7M | -$30.7M |
| Net income | -$36.7M | -$22.1M | -$42.2M | -$100,000.00 | -$330.5M | -$27.4M | -$8.0M | -$34.1M |
| Diluted EPS | -$0.41 | -$0.24 | -$0.47 | $0.00 | -$3.57 | -$0.29 | -$0.09 | -$0.36 |
| Operating cash flow | $2.6M | $700,000.00 | $6.6M | -$16.3M | -$13.6M | $21.1M | $10.6M | -$15.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 69.6% | 70.2% | 71.7% | 68.5% | 71.2% | 69.9% | 70.0% | 68.7% |
| Operating margin | -17.3% | -9.4% | -18.6% | -14.8% | -154.5% | -11.3% | -2.7% | -15.3% |
| Net margin | -17.4% | -10.4% | -20.0% | -0.1% | -155.1% | -13.3% | -3.8% | -17.0% |
Company news
Jul 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Donnelly Brian J· Chief Commerical Officer | Award | 5,000 | $3.94 | $19,680.00 | filing |
| 2026-06-11 | Raha Samraat S.· President and CEO | Award | 3,542 | $3.94 | $13,941.31 | filing |
| 2026-06-08 | Kumar Rashmi | Sale | 15,000 | $4.46 | $66,843.00 | filing |
| 2026-06-04 | Davis Mark Steven | Award | 59,701 | $0.00 | $0.00 | filing |
| 2026-06-04 | Dreismann Heiner | Award | 59,701 | $0.00 | $0.00 | filing |
| 2026-06-04 | Reitan Colleen F | Award | 59,701 | $0.00 | $0.00 | filing |
| 2026-06-04 | BISARO PAUL | Award | 59,701 | $0.00 | $0.00 | filing |
| 2026-06-04 | Kumar Rashmi | Award | 59,701 | $0.00 | $0.00 | filing |
| 2026-06-04 | Phanstiel S. Louise | Award | 59,701 | $0.00 | $0.00 | filing |
| 2026-06-04 | Skovronsky Daniel | Award | 59,701 | $0.00 | $0.00 | filing |
| 2026-06-04 | Newcomer Lee Nisley | Award | 59,701 | $0.00 | $0.00 | filing |
| 2026-06-01 | Jampa Raj· Chief Technology Officer | Award | 251,889 | $0.00 | $0.00 | filing |
| 2026-05-14 | BISARO PAUL | Buy | 7,500 | $3.69 | $27,637.50 | filing |
| 2026-05-01 | Donnelly Brian J· Chief Commerical Officer | Tax withholding | 55,975 | $4.80 | $268,680.00 | filing |
| 2026-04-14 | Verratti Mark· Chief Operating Officer | Tax withholding | 1,069 | $4.91 | $5,248.79 | filing |
| 2026-04-14 | Muzzey Dale· Chief Scientific Officer | Tax withholding | 946 | $4.91 | $4,644.86 | filing |
| 2026-03-22 | Verratti Mark· Chief Operating Officer | Tax withholding | 2,055 | $4.58 | $9,411.90 | filing |
| 2026-03-22 | Muzzey Dale· Chief Scientific Officer | Tax withholding | 2,019 | $4.58 | $9,247.02 | filing |
| 2026-03-22 | Wheeler Benjamin Richard· Chief Financial Officer | Tax withholding | 549 | $4.58 | $2,514.42 | filing |
| 2026-03-15 | Muzzey Dale· Chief Scientific Officer | Tax withholding | 11,949 | $4.66 | $55,682.34 | filing |
| 2026-03-15 | Verratti Mark· Chief Operating Officer | Tax withholding | 9,096 | $4.66 | $42,387.36 | filing |
| 2026-03-15 | Haas Kevin Richard· Chief Technology Officer | Tax withholding | 8,382 | $4.66 | $39,060.12 | filing |
| 2026-03-15 | Verratti Mark· Chief Operating Officer | Tax withholding | 5,611 | $4.66 | $26,147.26 | filing |
| 2026-03-15 | Muzzey Dale· Chief Scientific Officer | Tax withholding | 4,783 | $4.66 | $22,288.78 | filing |
| 2026-03-15 | Haas Kevin Richard· Chief Technology Officer | Tax withholding | 3,355 | $4.66 | $15,634.30 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.